In this study, we investigated the effect of
alpha-eudesmol, which potently inhibits the presynaptic
omega-agatoxin IVA-sensitive (P/Q-type) Ca(2+) channel, on
neurogenic inflammation following electrical stimulation of rat trigeminal ganglion. Treatment with
alpha-eudesmol (0.1-1 mg/kg. i.v.) dose-dependently attenuated neurogenic vasodilation in facial skin monitored by a
laser Doppler flowmetry. In addition,
alpha-eudesmol (1 mg/kg. i.v.) significantly decreased dural plasma extravasation in analysis using
Evans blue as a plasma marker. On the other hand,
alpha-eudesmol (1 mg/kg, i.v.) did not affect mean arterial blood pressure in rats. The
calcitonin gene-related peptide (CGRP) and
substance P (SP) released from activated sensory nerves have recently been suggested to be associated with the
neurogenic inflammation. In this study, we also showed that
alpha-eudesmol (0.45-45 microM) concentration-dependently inhibits the depolarization-evoked CGRP and SP release from sensory nerve terminals in spinal cord slices. These results indicate that the anti-
neurogenic inflammation action of
alpha-eudesmol, which does not affect the cardiovascular system, may be due to its presynaptic inhibition of the
neuropeptide release from perivascular trigeminal terminals. We also suggest that the
omega-agatoxin IVA-sensitive Ca(2+) channel blocker,
alpha-eudesmol, may become useful for the treatment of the
neurogenic inflammation in the trigemino-vascular system such as
migraine.